PSNL — Personalis, Inc.

Summary of Personalis Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $17.3 million, a 3% increase year-over-year (from $16.8 million).
• Full Year 2025 Revenue: $69.6 million, reflecting a transitional phase with a nearly $20 million decline in revenue from Natera.
• Clinical Tests Delivered: 6,183 tests in Q4, a 41% sequential increase and a 329% increase year-over-year. Over 16,000 tests delivered in 2025, up 394% from 2024.
• Biopharma Revenue: $10.9 million in Q4, down from $12.2 million year-over-year; full year biopharma revenue was $49 million, down from $51 million in 2024.
• Gross Margin: 11% in Q4 and 22.7% for the full year, with expectations of continued margin dilution into 2026 due to unreimbursed costs.
• Net Loss: $23.8 million in Q4 and $81.3 million for the full year, consistent with 2024.
• Cash Position: $240 million in cash and short-term investments, with an expected cash usage of approximately $100 million in 2026.

2. Strategic Updates and Business Highlights

• MRD Strategy Validation: The company is focused on scaling its NeXT Personal test, which has gained significant traction among oncologists.
• Medicare Coverage: Achieved two Medicare coverage decisions for breast and lung cancer, enhancing the legitimacy and market position of the NeXT Personal test.
• Clinical Evidence Generation: Significant progress in building clinical evidence with over 35 ongoing studies, including landmark studies that support the efficacy of their MRD tests.
• Innovation: Introduction of the real-time variant tracker report, allowing for dynamic monitoring of cancer mutations, which has received positive feedback from clinicians.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $78 million and $80 million, with clinical revenue projected at $10 million to $11 million from newly covered tests.
• Growth Expectations: Anticipates strategic revenue growth from approximately $14 million in 2025 to $30 million to $32 million in 2026, driven by quadrupling clinical volumes.
• Clinical Volume Guidance: Initial guidance set at 43,000 to 45,000 tests for 2026, representing a 170% year-over-year growth.

4. Bad News, Challenges, or Points of Concern

• Revenue Transition: The shift from lower-margin project work to higher-value MRD partnerships has resulted in significant revenue declines from previous contracts, particularly with Natera.
• Margin Compression: Expected continued gross margin dilution in 2026, particularly in Q1, due to unreimbursed costs associated with scaling clinical volumes.
• Biopharma Sector Stability: While biopharma revenue grew significantly, there are concerns about the stability of spending in the sector and potential delays in contract renewals.
• Competitive Landscape: Increased competition in the MRD space, with new entrants and consolidation among larger players, poses a risk to market share.

5. Notable Q&A Insights

• Reimbursement Impact: The recent Medicare coverage has improved clinician receptivity and ordering rates, enhancing the company's market position.
• Biopharma Contracts: No significant pushouts or cancellations observed in biopharma contracts, indicating stability in that segment.
• Clinical Volume Composition: A significant portion of clinical tests currently run are not reimbursed, with ongoing efforts to expand coverage and increase the number of oncologists ordering tests.
• Operational Efficiency: The company is focused on optimizing lab operations and automation to improve margins as clinical volumes ramp up.
• Future Reimbursement Submissions: Plans to pursue reimbursement for neoadjuvant breast cancer and colorectal cancer, with ongoing evidence generation to support these initiatives.

Overall, Personalis is positioned for growth in the MRD testing market, with a strong emphasis on clinical evidence and reimbursement strategies, despite facing challenges related to revenue transitions and competitive pressures.